Pharmaceuticals, Biotechnology and Life Sciences
Novartis has reported new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.
Congressional Republicans recrafted their Obamacare replacement bill on Monday in hopes of satisfying critics as U.S. President Donald Trump prepared to promote his first major legislative initiative on Capitol Hill.
Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURETM XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
Bristol-Myers Squibb and CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, have expanded their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform.
Eli Lilly’s phase 3 double-blind study (MONARCH 2) designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced (locoregionally recurrent or metastatic) breast cancer has met its primary endpoint.
Arix Bioscience, the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds have signed agreement to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.
ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of immunotherapy products for the treatment of allergies, has appointed Gerd Zettlmeissl as its new Chairman of the Board, Béatrice De Vos having stood down to focus on new projects.
Array BioPharma said on Sunday it has exited the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products 2 its new drug application (NDA) for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutationally-driven subset of skin cancer.
AstraZeneca has reported results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i).
AB Science pharmaceutical company, specialist in the protein kinase inhibitors (PKIs), said on Monday that it had the first successful phase 3 trial of a tyrosine kinase inhibitor in the treatment of amyotrophic lateral sclerosis (ALS).